Alendronate Therapy in Polyostotic Fibrous Dysplasia Presenting With Pathologic Fracture

Abstract not available. Introduction provided instead.

Polyostotic fibrous dysplasia (PFD) is characterized by developmental failure in the remodeling of primitive bone to mature lamellar bone. PFD presents with bone pain, increased bone fragility, deformities, and fractures. Bisphosphonates are the only agents available for medical management.^1,2 Intravenous (IV) pamidronate is the established treatment for symptomatic bone involvement in PFD.^3,4 Oral alendronate holds promise because of its comparable outcomes, lower cost, and ease of administration.⁵